Document |
Document Title |
WO/2024/036295A1 |
The disclosure relates to conjugates of the formulae (I) and (II): wherein the variables R1, R2, R3, R17, R18, R19, R20, R20A, R21, and G are defined herein, as well as methods for the use of the conjugates, and kits including the conjug...
|
WO/2024/026102A2 |
Prodrugs of testosterone and their use in alleviating, improving or reducing a risk of developing one or more conditions associated with androgen deprivation therapy (ADT), including orchiectomy or administration of a luteinizing hormone...
|
WO/2024/013678A1 |
The present disclosure relates to a compound (7beta-methylandrost-4-ene-3,17-dione) for use in medicine, in particular for use in any condition susceptible of being improved or prevented by the inhibition of aromatase, in particular for ...
|
WO/2023/242712A1 |
The present invention refers to the sector of the processes for the preparation of active ingredients for pharmaceutical use, and in particular to a process for the purification on industrial scale of (17β)-2-methoxy-estra-1,3,5(10)-tri...
|
WO/2023/218448A1 |
Provided is a method of increasing lipid synthesis or accumulation in mammary epithelial cells (MECs) culture and optionally secretion therefrom The method comprising contacting the MECs with an LXR agonist in the presence of a fatty aci...
|
WO/2023/211856A1 |
The disclosure relates to methods of treating a neurological disorder, such as epilepsy or an epilepsy syndrome, with Compound 1 or pharmaceutically acceptable salts thereof, alone, or in combination with sodium ion (Na+) channel blockers.
|
WO/2023/209261A1 |
The present invention relates to the in vitro use of ethinylestradiol to increase the growth of lipid-enveloped viruses, in particular SARS-CoV-2 and influenza A virus (IAV). The invention also relates to a method for increasing the in v...
|
WO/2023/209017A1 |
The present invention relates to a process for the preparation of a compound of formula (I), a stereoisomer, a salt, a hydrate or a solvate thereof, comprising the step of desulfinylation of a compound of formula (II) to produce compound...
|
WO/2023/185673A1 |
Provided in the present invention are CDK8 inhibitors, a preparation method therefor and the use thereof, belonging to the field of biological medicines. The CDK8 inhibitors of the present invention are compounds represented by formula (...
|
WO/2023/172132A1 |
The present disclosure relates to compounds suitable for the inhibition of Δ24-dehydrocholesterol reductase (DHCR24), particularly the selective inhibition of DHCR24. These compounds are for use as therapeutic agents, in particular, age...
|
WO/2023/151623A1 |
A preparation method for a natural bufogenin compound, comprising: taking cheap and easily available commercial steroid skeleton materials such as androstenedione 4-AD or 3β-hydroxyl-5β-androstane-17-ketone; performing simple conversio...
|
WO/2023/137529A1 |
The present invention relates to compounds which are active against parasitic infections, such as protozoan parasite infections (including flagellate parasite infections, ciliate parasite infections, amoeba parasite infections and apicom...
|
WO/2023/133507A1 |
Estradiol compounds and methods of using the same for treating diseases and conditions including depressive disorder, an anxiety disorder, post-traumatic stress disorder (PTSD), drug addiction, schizophrenia, Alzheimer's dementia, Parkin...
|
WO/2023/133502A1 |
The present disclosure provides methods of treating and preventing trigeminal nerve pain with modulators of oxidative stress (e.g., NRF2 transcription network activators and/or inhibitors of transient receptor potential ankyrin 1 (TRPA1)...
|
WO/2023/126014A1 |
An estrone synthesis method. The method comprises the following steps: 1) performing aromatization reaction, uniformly mixing estra-4,9-diene-3,17-dione, acetic anhydride, and dichloromethane that serve as raw materials, adding acetyl br...
|
WO/2023/094418A1 |
The present application relates to a metal-free photocatalytic method and system for converting polystyrene into benzoic acid, using a metal free catalytic system. In particular, the method and system described herein allow to generate b...
|
WO/2023/083979A1 |
The present disclosure concerns the novel compounds 3α-ethyl-3β-hydroxy-5α-androstan-17-one and 3α-ethyl-3β-hydroxy-5α-androstan-17-one, the medical use thereof and in particular use in the treatment of diseases and disorders assoc...
|
WO/2023/083978A1 |
The present disclosure concerns the novel compound 3. alpha.- ethynyl-3. beta.-hydroxy-5. alpha.-androstan-17-methoxime, the medical use thereof and in particular use in the treatment of diseases and disorders associated with an a3 subty...
|
WO/2023/051937A1 |
The present invention relates to a process for preparing (15α,16α,17β)-estra-1,3,5(10)-triene-3,15,16,17-tetrol, also known as Estetrol, and Estetrol monohydrate, having the formulas shown below: Formulae (I) (II)
|
WO/2023/021026A1 |
A method of preparing a compound of Formula (VI) is provided wherein: R1, R2 and R3 are independently selected from H, halogen or methyl; and, Pr2 is -Q2, -C(O)Q2 or -Si(Q2)3 wherein each Q2 is independently selected from C1-C6 alkyl, C1...
|
WO/2023/001866A1 |
A process for the preparation of a compound of formula (IIa) is described where A is a silyl protecting group, in high diastereoisomeric purity and in crystalline form, comprising the crystallization of a mixture of the compound of formu...
|
WO/2023/278289A1 |
Certain embodiments are directed to modified glucocorticoid compounds having one or both of (i) a substitution of a halogen for the 11 hydroxy and/or (ii) reduction of the bond between carbon 4 and carbon 5 of the A ring.
|
WO/2022/257895A1 |
The present invention relates to an intermediate for fulvestrant and a preparation method therefor. Specifically, the present invention relates to a compound of formula V and a preparation method therefor, wherein R1 is hydrogen or hydro...
|
WO/2022/245532A1 |
Disclosed herein is a pharmaceutical composition comprising solid state forms of 17-ethynyl-10R, 13S-dimethyl 2, 3, 4, 7, 8R, 9S, 10, 11, 12, 13, 14S, 15, 16, 17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R, 7R, 17S-triol. Also disclose...
|
WO/2022/225999A1 |
Provided herein are methods for treating, preventing, minimizing and/or substantially inhibiting inflammation associated with a respiratory virus such as COVID-19 and/or acute respiratory distress syndrome (ARDS), comprising administerin...
|
WO/2022/204184A1 |
The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
|
WO/2022/198191A1 |
The present disclosure relates to polycyclic (e.g., tetracyclic) androgen receptor (AR) modulators, synthetic methods for preparing such AR modulators, and methods of using such AR modulators to treat an androgen-dependent condition, suc...
|
WO/2022/106574A1 |
Object of the present invention is an improved process for the preparation of Trenbolone (I-b) and/or Trenbolone Acetate (I-a) comprising the reaction of the compound of formula (II): wherein R is H or Ac; with an oxidant agent in presen...
|
WO/2022/106566A1 |
Object of the present invention is an improved process for the preparation of Trenbolone Acetate of formula (I) having irregular hexagon plates crystal habit and/or a median value (D50) of the particle size distribution comprised in the ...
|
WO/2022/055542A1 |
Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkag...
|
WO/2022/006145A1 |
The present disclosure relates to compositions derived from bioreachable molecules, such as amino acids and/or steroids. In particular, the composition can be a monomer, a polymer, or a copolymer derived from an amino acid dimer. Such co...
|
WO/2021/262836A1 |
Provided herein is a compound of the Formula (I) or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3a, R4a, R4b, R5, R6, R7, R11a, R11b, R15a, R15b, R16,R17, R19, RX, RY, and t are defined herein. Also provided herein are...
|
WO/2021/252761A2 |
Disclosed herein are monomeric and oligomeric compound embodiments for use as contraceptive agents. Monomeric compound embodiments disclosed herein comprise substituents that facilitate the ability of the compounds to exhibit progestogen...
|
WO/2021/252459A1 |
The present disclosure describes compositions and methods for deactivating coronavirus. A method includes providing a deactivation composition including one or more CSA compounds and a carrier, administering the deactivation composition ...
|
WO/2021/237371A1 |
The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected ...
|
WO/2021/226465A1 |
The present disclosure relates to polycyclic (e.g., tetracyclic) glucocorticoid receptor (GR) modulators, synthetic methods for preparing such GR modulators, and methods of using such GR modulators to treat a glucocorticoid-dependent con...
|
WO/2021/175751A1 |
The present disclosure generally provides 11-oxo-cucurbitane compounds, including various glycosides, and the use of such compounds and related compounds as flavor modifiers. In some aspects, the disclosure provides compositions that inc...
|
WO/2021/167008A1 |
This method for producing an aromatic astatine compound comprises reacting aromatic iodonium ylide with astatine to produce an aromatic astatine compound.
|
WO/2021/104503A1 |
Disclosed is a method for preparing β-carbonyl sulfone. The method comprises: by taking an α-carbonyl diazo compound and sodium arylsulfinate as reaction substrates, cheap silver nitrate as an optimal catalyst, 1,10-phenanthroline as a...
|
WO/2021/080880A1 |
N-methyl-d-aspartate receptors (NMDAR) and/or potentiating y-aminobutyric acid receptors (GABAAR) agents and uses thereof are described. Uses of these agents include methods of treating or preventing various psychiatric diseases, disorde...
|
WO/2021/075860A1 |
The present invention relates to novel 2-Methoxyestradiol derivatives and their medical use. In particular, the novel derivatives of the present invention are useful for the treatment or prevention of liver or lung fibrosis. Accordingly,...
|
WO/2021/069570A1 |
Compounds and compositions for the activation of SERCA2a are disclosed. In particular, provided are compounds that act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na+/K+ ATPase. In general, the d...
|
WO/2021/058716A1 |
The present invention relates to a process for preparing (15α,16α,17β)-Estra-1,3,5(10)-triene-3,15,16,17-tetrol, also known as Estetrol, having the formula shown below: (I)
|
WO/2021/044302A1 |
The invention relates to the preparation of estetrol of formula (I), derivatives thereof protected at positions 3,15α,16α,17β of general formula (III), and 3-hydroxy derivatives thereof protected at positions 15α,16α,17β of general...
|
WO/2021/012673A1 |
Disclosed is a method for preparing trenbolone acetate, same belonging to the technical fields of preparation and processing of hormone drugs. According to the method, 3-ethylenedioxy-estra-[delta]5,10, [delta]9,11-dien-17-one is used as...
|
WO/2020/264512A1 |
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...
|
WO/2020/264495A1 |
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...
|
WO/2020/243488A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...
|
WO/2020/223174A1 |
Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cel...
|
WO/2020/187965A1 |
The invention relates to an efficient and industrially applicable process for the preparation and purification of allopregnanolone and intermediates thereof without the assistance of column chromatography.
|